New epilepsy drug RAP-219 enters final testing phase

NCT ID NCT07563881

Recruiting now Disease control Sponsor: Rapport Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 8 times

Summary

This study tests an experimental drug called RAP-219 in 333 adults with focal seizures (a type of epilepsy). The goal is to see if the drug safely reduces how often seizures happen compared to a placebo. Participants must be 18-75, have had focal epilepsy for at least 2 years, and take 1-3 other seizure medicines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPSY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPSY FOCAL EPILEPSY FOCAL SEIZURE

Contacts and locations

Locations

Amicis Research Center
RECRUITING

Palmdale, California, 91324, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44109, United States
Consultants in Epilepsy & Neurology, PLLC
RECRUITING

Boise, Idaho, 83702, United States
Emory Brain Health Center
RECRUITING

Atlanta, Georgia, 30329, United States
Indiana University Health Fort Wayne Neurology
RECRUITING

Fort Wayne, Indiana, 46804, United States
Mid-Atlantic Epilepsy and Sleep Center
RECRUITING

Bethesda, Maryland, 20817, United States
Neurological Associates
RECRUITING

Richmond, Virginia, 23236, United States
Northeast Regional Epilepsy Group
RECRUITING

Hackensack, New Jersey, 07601, United States
Panhandle Research and Medical Clinic, LLC
RECRUITING

Gulf Breeze, Florida, 32561, United States
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.